Anticoagulation for extended venous thromboembolism treatment: less is really more
- PMID: 40023636
- DOI: 10.1016/S0140-6736(25)00099-6
Anticoagulation for extended venous thromboembolism treatment: less is really more
Conflict of interest statement
SM reports receiving honoraria from AstraZeneca, Alveron, Bayer, Hemab, Norgine, Sanofi, Sirius, VarmX, and Viatris for advisory or data safety monitoring boards, or educational activities, all outside the submitted work. All honoraria are paid to her institution. JL reports receiving honoraria from AstraZeneca, Viatris, and Bristol Myers Squibb–Pfizer for advisory boards or educational activities, all outside the submitted work. All honoraria are paid to her institution.
Comment on
-
Extended treatment of venous thromboembolism with reduced-dose versus full-dose direct oral anticoagulants in patients at high risk of recurrence: a non-inferiority, multicentre, randomised, open-label, blinded endpoint trial.Lancet. 2025 Mar 1;405(10480):725-735. doi: 10.1016/S0140-6736(24)02842-3. Lancet. 2025. PMID: 40023651 Clinical Trial.
Publication types
LinkOut - more resources
Full Text Sources